title: Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
abstract: Pretreatment with clopidogrel before elective primary percutaneous coronary intervention (PCI) has been shown to reduce ischemic complications. There are limited data about the value of clopidogrel pretreatment in the setting of PCI for ST-elevation myocardial infarction (STEMI). We aimed to examine the effect of clopidogrel preloading on angiographic and clinical outcomes in patients with STEMI who were treated with PCI. We conducted a prospective registry of all patients treated with primary PCI for STEMI from March 2003 to June 2006. Excluded were patients with cardiogenic shock. For the current analysis, patients (n = 292) were allocated into 2 groups. One group received clopidogrel loading dose before PCI (in the emergency department or coronary care unit, n = 165); the other,immediately after PCI (n = 127). TIMI myocardial perfusion (TMP) grade at the end of PCI and 30-day and 6-month clinical outcomes were assessed. Clinical characteristics were similar among the groups. However, patients pretreated with clopidogrel were more likely to receive aspirin and beta blockers before the current admission. TMP grade 3 occurred in a higher proportion of patients in the clopidogrel pretreatment group than in the no-pretreatment group (85% vs 71%, p = 0.01). Multivariate logistic regression analysis showed that clopidogrel pretreatment was associated with an odds ratio of 2.2 for TMP grade 3 (1.2 to 3.9, p = 0.01). Furthermore, the incidence of reinfarction at 30 days was lower in the pretreatment group (0% vs 3.2%, respectively, p = 0.04). In conclusion, these findings support the early use of clopidogrel in patients with STEMI who are treated with primary PCI.
authors.affiliation: Cardiology Department, Rabin Medical Center, Petah-Tikva; and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. elev@tmh.tmc.edu
authors.forename: Eli I
authors.initials: EI
authors.lastname: Lev
authors.forename: Ran
authors.initials: R
authors.lastname: Kornowski
authors.forename: Hana
authors.initials: H
authors.lastname: Vaknin-Assa
authors.forename: David
authors.initials: D
authors.lastname: Brosh
authors.forename: Shmuel
authors.initials: S
authors.lastname: Fuchs
authors.forename: Alexander
authors.initials: A
authors.lastname: Battler
authors.forename: Abid
authors.initials: A
authors.lastname: Assali
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000077144:Clopidogrel; D017023:Coronary Angiography; D003326:Coronary Circulation; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011292:Premedication; D011446:Prospective Studies; D012008:Recurrence; D012042:Registries; D019233:Retreatment; D015607:Stents; D013927:Thrombosis / Q000453:epidemiology; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine